Randomized placebo-controlled trial of oral tannin supplementation on COVID-19 symptoms, gut dysbiosis and cytokine response.
AUC, area-under-curve
COVID-19
COVID-19, Coronavirus disease 2019
Dysbiosis
Gut microbiota
HC, Non COVID-19 healthy controls
LEFSe, Linear discriminant analysis effect size
SARS-CoV-2, severe acute respiratory syndrome coronavirus 2
Serum cytokines
Tannins
Journal
Journal of functional foods
ISSN: 1756-4646
Titre abrégé: J Funct Foods
Pays: Netherlands
ID NLM: 101513493
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
27
08
2022
revised:
02
11
2022
accepted:
29
11
2022
pubmed:
6
12
2022
medline:
6
12
2022
entrez:
5
12
2022
Statut:
ppublish
Résumé
The clinical study aim was to investigate whether a tannin-based dietary supplementation could improve the efficacy of standard-of-care treatment of hospitalized COVID-19 patients by restoring gut microbiota function. Adverse events and immunomodulation post-tannin supplementation were also investigated. A total of 124 patients receiving standard-of-care treatment were randomized to oral tannin-based supplement or placebo for a total of 14 days. Longitudinal blood and stool samples were collected for cytokine and 16S rDNA microbiome profiling, and results were compared with 53 healthy controls. Although oral tannin supplementation did not result in clinical improvement or significant gut microbiome shifts after 14-days, a reduction in the inflammatory state was evident and significantly correlated with microbiota modulation. Among cytokines measured, MIP-1α was significantly decreased with tannin treatment (p = 0.03) where it correlated positively with IL-1β and TNF- α, and negatively with stool
Identifiants
pubmed: 36467850
doi: 10.1016/j.jff.2022.105356
pii: S1756-4646(22)00426-1
pmc: PMC9708634
doi:
Types de publication
Journal Article
Langues
eng
Pagination
105356Subventions
Organisme : NIAID NIH HHS
ID : K24 AI121296
Pays : United States
Organisme : NIAID NIH HHS
ID : P01 AI152999
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK056338
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI148342
Pays : United States
Informations de copyright
© 2022 The Authors. Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Nucleic Acids Res. 2013 Jan 7;41(1):e1
pubmed: 22933715
EMBO J. 2010 Dec 1;29(23):3952-66
pubmed: 20959807
Front Microbiol. 2021 Mar 16;12:625782
pubmed: 33796085
Nat Methods. 2016 Jul;13(7):581-3
pubmed: 27214047
Anim Nutr. 2021 Dec 29;8:350-360
pubmed: 35510031
Sci Rep. 2021 May 12;11(1):10103
pubmed: 33980943
J Dig Dis. 2020 Mar;21(3):125-126
pubmed: 32096611
Sci Rep. 2020 Dec 10;10(1):21697
pubmed: 33303843
Front Microbiol. 2021 Sep 17;12:732838
pubmed: 34603261
J Med Food. 2014 May;17(5):550-7
pubmed: 24325454
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Gut. 2021 Apr;70(4):698-706
pubmed: 33431578
Trials. 2021 Apr 28;22(1):310
pubmed: 33910614
J Exp Med. 2014 Nov 17;211(12):2397-410
pubmed: 25366965
Cytokine. 2018 Apr;104:8-13
pubmed: 29414327
Microbiome. 2018 Aug 9;6(1):140
pubmed: 30092815
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
Gastroenterology. 2020 Sep;159(3):944-955.e8
pubmed: 32442562
ACS Nano. 2020 May 26;14(5):5179-5182
pubmed: 32356654
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Front Immunol. 2018 Feb 12;9:182
pubmed: 29483910
Exp Lung Res. 1994 Nov-Dec;20(6):473-90
pubmed: 7882902
Front Microbiol. 2022 Apr 27;13:848611
pubmed: 35572677
J Infect Dis. 2020 Aug 4;222(5):746-754
pubmed: 32563194
Clin Exp Immunol. 2004 Apr;136(1):95-103
pubmed: 15030519
Transl Res. 2020 Dec;226:57-69
pubmed: 32827705